ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice

H. V. Reddi, P. Madde, A. J. Reichert-Eberhardt, Evanthia Galanis, John A III Copland, B. McIver, S. K G Grebe, N. L. Eberhardt

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Anaplastic thyroid carcinoma (ATC) is the most aggressive thyroid cancer variant, accounting for 1-2% of all cases, but 33% of deaths, and exhibiting an average life expectancy of 5 months. ATC is largely unresponsive to radioactive iodine, chemotherapy, external beam radiation or surgery, underscoring the need for new and effective therapies. We evaluated the therapeutic potential of an oncolytic adenovirus, ONYX-411, that replicates selectively in and kills cells with dysfunction of the retinoblastoma (RB) pathway. In the present study, we report that ONYX-411 is able to induce cell death in eight human anaplastic carcinoma cell lines in vitro. The cytopathic effect of the virus is specific to cells with RB dysfunction, which appears to be frequent in ATC. We confirmed the expression of the coxsackie adenovirus receptor, CAR, in all ATC cell lines, demonstrating the potentially universal application of this oncolytic viral therapy to ATC. In addition, the growth of xenograft tumors induced in athymic mice with the ARO and DRO cell lines was significantly reduced by ONYX-411 treatment. These results indicate that ONYX-411 can be a potential therapeutic agent for the treatment of ATC, rendering this class of conditionally replicating adenoviruses an attractive candidate for clinical trials.

Original languageEnglish (US)
Pages (from-to)750-757
Number of pages8
JournalCancer Gene Therapy
Volume15
Issue number11
DOIs
StatePublished - Nov 2008

Fingerprint

Heterografts
Adenoviridae
Nude Mice
Cell Death
Cell Line
Growth
Neoplasms
Retinoblastoma
Coxsackie and Adenovirus Receptor-Like Membrane Protein
Therapeutics
Life Expectancy
Thyroid Neoplasms
Iodine
Anaplastic Thyroid Carcinoma
Clinical Trials
Radiation
Viruses
Carcinoma
Drug Therapy

Keywords

  • Anaplastic thyroid carcinoma
  • Novel therapeutic agent
  • ONYX-411
  • Retinoblastoma dysfunction

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Molecular Biology

Cite this

ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice. / Reddi, H. V.; Madde, P.; Reichert-Eberhardt, A. J.; Galanis, Evanthia; Copland, John A III; McIver, B.; Grebe, S. K G; Eberhardt, N. L.

In: Cancer Gene Therapy, Vol. 15, No. 11, 11.2008, p. 750-757.

Research output: Contribution to journalArticle

@article{825bb7dcfbb34cdfb53cfa351cbaa47e,
title = "ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice",
abstract = "Anaplastic thyroid carcinoma (ATC) is the most aggressive thyroid cancer variant, accounting for 1-2{\%} of all cases, but 33{\%} of deaths, and exhibiting an average life expectancy of 5 months. ATC is largely unresponsive to radioactive iodine, chemotherapy, external beam radiation or surgery, underscoring the need for new and effective therapies. We evaluated the therapeutic potential of an oncolytic adenovirus, ONYX-411, that replicates selectively in and kills cells with dysfunction of the retinoblastoma (RB) pathway. In the present study, we report that ONYX-411 is able to induce cell death in eight human anaplastic carcinoma cell lines in vitro. The cytopathic effect of the virus is specific to cells with RB dysfunction, which appears to be frequent in ATC. We confirmed the expression of the coxsackie adenovirus receptor, CAR, in all ATC cell lines, demonstrating the potentially universal application of this oncolytic viral therapy to ATC. In addition, the growth of xenograft tumors induced in athymic mice with the ARO and DRO cell lines was significantly reduced by ONYX-411 treatment. These results indicate that ONYX-411 can be a potential therapeutic agent for the treatment of ATC, rendering this class of conditionally replicating adenoviruses an attractive candidate for clinical trials.",
keywords = "Anaplastic thyroid carcinoma, Novel therapeutic agent, ONYX-411, Retinoblastoma dysfunction",
author = "Reddi, {H. V.} and P. Madde and Reichert-Eberhardt, {A. J.} and Evanthia Galanis and Copland, {John A III} and B. McIver and Grebe, {S. K G} and Eberhardt, {N. L.}",
year = "2008",
month = "11",
doi = "10.1038/cgt.2008.44",
language = "English (US)",
volume = "15",
pages = "750--757",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice

AU - Reddi, H. V.

AU - Madde, P.

AU - Reichert-Eberhardt, A. J.

AU - Galanis, Evanthia

AU - Copland, John A III

AU - McIver, B.

AU - Grebe, S. K G

AU - Eberhardt, N. L.

PY - 2008/11

Y1 - 2008/11

N2 - Anaplastic thyroid carcinoma (ATC) is the most aggressive thyroid cancer variant, accounting for 1-2% of all cases, but 33% of deaths, and exhibiting an average life expectancy of 5 months. ATC is largely unresponsive to radioactive iodine, chemotherapy, external beam radiation or surgery, underscoring the need for new and effective therapies. We evaluated the therapeutic potential of an oncolytic adenovirus, ONYX-411, that replicates selectively in and kills cells with dysfunction of the retinoblastoma (RB) pathway. In the present study, we report that ONYX-411 is able to induce cell death in eight human anaplastic carcinoma cell lines in vitro. The cytopathic effect of the virus is specific to cells with RB dysfunction, which appears to be frequent in ATC. We confirmed the expression of the coxsackie adenovirus receptor, CAR, in all ATC cell lines, demonstrating the potentially universal application of this oncolytic viral therapy to ATC. In addition, the growth of xenograft tumors induced in athymic mice with the ARO and DRO cell lines was significantly reduced by ONYX-411 treatment. These results indicate that ONYX-411 can be a potential therapeutic agent for the treatment of ATC, rendering this class of conditionally replicating adenoviruses an attractive candidate for clinical trials.

AB - Anaplastic thyroid carcinoma (ATC) is the most aggressive thyroid cancer variant, accounting for 1-2% of all cases, but 33% of deaths, and exhibiting an average life expectancy of 5 months. ATC is largely unresponsive to radioactive iodine, chemotherapy, external beam radiation or surgery, underscoring the need for new and effective therapies. We evaluated the therapeutic potential of an oncolytic adenovirus, ONYX-411, that replicates selectively in and kills cells with dysfunction of the retinoblastoma (RB) pathway. In the present study, we report that ONYX-411 is able to induce cell death in eight human anaplastic carcinoma cell lines in vitro. The cytopathic effect of the virus is specific to cells with RB dysfunction, which appears to be frequent in ATC. We confirmed the expression of the coxsackie adenovirus receptor, CAR, in all ATC cell lines, demonstrating the potentially universal application of this oncolytic viral therapy to ATC. In addition, the growth of xenograft tumors induced in athymic mice with the ARO and DRO cell lines was significantly reduced by ONYX-411 treatment. These results indicate that ONYX-411 can be a potential therapeutic agent for the treatment of ATC, rendering this class of conditionally replicating adenoviruses an attractive candidate for clinical trials.

KW - Anaplastic thyroid carcinoma

KW - Novel therapeutic agent

KW - ONYX-411

KW - Retinoblastoma dysfunction

UR - http://www.scopus.com/inward/record.url?scp=53549107470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53549107470&partnerID=8YFLogxK

U2 - 10.1038/cgt.2008.44

DO - 10.1038/cgt.2008.44

M3 - Article

C2 - 18583996

AN - SCOPUS:53549107470

VL - 15

SP - 750

EP - 757

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 11

ER -